Di-deuterated linoleic acid ethyl ester
Small moleculeexperimental
Deulinoleate ethyl is an experimental, orally-bioavailable synthetic deuterated polyunsaturated fatty acid (PUFA), a part of reinforced lipids. It is an isotopologue of linoleic acid, an essential omega-6 PUFA. The deuterated compound, while identical to natural linoleic acid except for the presence of deuterium, is resistant to lipid peroxidation which makes studies of its cell-protective properties worthwhile. — Wikipedia
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Oct 31, 2019 (NCT04102501)
Timeline
Indications
Mechanism of action
- Unspecified targetAntioxidant
antioxidant
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDeulinoleate ethyl ↗
- WikipediaDi-deuterated linoleic acid ethyl ester ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04937530 | Phase 2 | Jun 23, 2021 | Ludwig Maximilians University, Retrotope, Inc. |
| NCT04762589 | Phase 2 | Mar 10, 2021 | Retrotope, Inc., Utrecht University |
| NCT04102501 | Phase 3 | Oct 31, 2019 | Retrotope, Inc., University of California, San Francisco |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Retrotope, Inc. | For profit | 3 | 3 | 2 | 2019 |
| Ludwig Maximilians University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Utrecht University | Academic/Hospital | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1